Journey Medical (DERM) announced that a data analysis from two Phase 3 multicenter clinical trials, evaluating Emrosi for the treatment of moderate-to-severe papulopustular rosacea in adults will be ...

In a follow up investigation into the multibillion dollar drug ticagrelor, The BMJ has uncovered fresh concerns, this time in ...

CHICAGO, IL / ACCESS Newswire / June 20, 2025 / Dr. John Peloza, internationally recognized spine surgeon and innovator in ...

Phase 3 trials have demonstrated that enlicitide decanoate significantly reduces LDL cholesterol, showing strong potential as ...

This is a pivotal moment, said Paul Aisen, M.D., founding director of ATRI. We're now on a course toward prevention, with ...

In this interview with TRUST-I and TRUST-II trial investigator, Jorge J. Nieva, MD, USC Keck School of Medicine, he walks through the design of the trials, the results that supported the FDA approval, ...

VANCOUVER, BC / ACCESS Newswire / June 20, 2025 / Onco-Innovations Limited(CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that the Co-Founders of ...

EMA committee recommends marketing approval for Bayer’s Nubeqa for patients with advanced prostate cancer: Berlin Saturday, June 21, 2025, 10:00 Hrs [IST] The Committee for Medi ...

People living with Sickle Cell Disease (SCD) in Nigeria have lamented that the high cost of medication and poor access to comprehensive care are weighing heavily on them and their families.

This regulatory approval is the second for VYVGART SC in Europe, which first received approval as an add-on to standard therpy for the treatment of adult patients with generalized myasthenia gravis ...